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Is urate crystal precipitation a predictor of
cardiovascular risk in hyperuricemic
patients? A Danish cohort study
Kasper Søltoft Larsen1,2*, Anton Pottegård2, Hanne Lindegaard3 and Jesper Hallas1,2
Abstract
Introduction: There is increasing evidence that both hyperuricemia and gout increase the risk of cardiovascular
morbidity and mortality. Whether urate crystal precipitation confers a particular risk above what is already inherent
in having hyperuricemia is not well established. We conducted this cohort study to establish whether the presence
of monosodium urate crystal precipitation per se is associated with increased risk of cardiovascular diseases among
hyperuricemic patients.
Methods: We identified hyperuricemic individuals who had joint fluid examinations for urate crystals. Individuals
with intra-articular urate crystals were matched by propensity score to individuals without crystals and compared
with respect to a composite cardiovascular endpoint. Included in the propensity score model were potential
confounders retrieved from four different health care registries.
Results: We identified 862 hyperuricemic patients having urate crystal examination. After propensity score matching,
we could include 317 patients with urate crystals matched 1:1 to patients without urate crystals. We found no
difference between the two groups with respect to cardiovascular outcomes (hazard ratios = 0.86; 95 % confidence
interval (CI) 0.52 - 1.43) or death (hazard ratio 0.74; CI 0.45 - 1.21).
Conclusion: The presence of urate crystal precipitations does not seem to confer a particular cardiovascular risk in
hyperuricemic patients.
Keywords: Urate crystal precipitations, Cardiovascular risk, Hyperuricemia
Introduction
Recent epidemiological studies have indicated that hy-
peruricemia with or without gout increases the risk of
cardiovascular diseases and mortality [1–6]. The primary
cause of gout is hyperuricemia, and increasing levels of
urate increase the risk of monosodium urate (MSU)
crystal precipitations, which is the defining criterion of
gout [7]. Whether there is an increased cardiovascular
risk with asymptomatic hyperuricemia has been heavily
debated without any consensus having emerged [8, 9],
but the most recent papers have leaned towards the
recognition of a true, causal relationship between hyper-
uricemia and cardiovascular disease [10–12].
Despite the increasing evidence that both hyperurice-
mia and gout are associated with cardiovascular disease,
no studies have, to our knowledge, attempted to address
whether MSU precipitation confers a particular risk of
cardiovascular disease above what is already inherent in
having hyperuricemia. From a pathophysiological view-
point, such a notion would be plausible. Gouty arthritis
is associated with increased acute and chronic inflamma-
tion [13], and inflammation is prothrombogenic and can
result in ischemic cardiovascular events [14, 15].
We conducted this cohort study to establish whether
the presence of MSU crystal joint precipitation per se is
associated with increased risk of cardiovascular out-
comes among hyperuricemic patients. If a link between
MSU precipitation and cardiovascular disease could be
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established, it would favor a more aggressive approach
to urate-lowering therapy in patients with gout [16].
Methods
We conducted this cohort study in Funen County,
Denmark (approximately 485,000 inhabitants) using Danish
health care registries furnished by the Danish health
authorities. We identified all hyperuricemic individuals
who had synovial fluid examined for MSU crystals and
compared individuals with MSU crystals to those without
MSU crystals with respect to the occurrence of cardiovas-
cular outcomes. Confounders were controlled by the use
of propensity score matching and multivariable modeling.
Data sources
Denmark offers unique possibilities for epidemiological
research with population-based registries that combined
with the unique personal identifier, the Danish Central
Person Registry Code [17], provide perfect individual-
level record linkage. In Denmark, virtually all health
services are provided by the public health authorities,
which allows true population-based epidemiological
studies [18].
Using the central person registry code, we linked the
four following registries:
1. The laboratory database of Odense University
Hospital (OUHLab), a clinical laboratorial system
that contains information on all blood samples
analyzed in various hospital laboratories in the
Funen County since November 1992. The OUHLab
includes primary and secondary health care
providers, for both inpatients and outpatients.
It also covers valid information on synovial fluid
examinations including MSU crystals since 1999.
Trained staff at the OUHLab carried out all MSU
crystal examinations. Not covered by the database
are some blood samples analyzed at general
practitioners’ offices with independent equipment.
All urate concentration measurements were covered.
2. The Odense University Pharmaco-Epidemiological
Database is a prescription database holding
information on redeemed, reimbursed prescriptions
for the citizens of Funen County since 1990 [19].
Data included are identifiers of the prescription
holder, a full account of the dispensed product, the
date of dispensing and a demographic module
with information on birth, death, migration and
residency, which allowed appropriate censoring. The
product is described in terms of the defined daily
dose and the anatomical–therapeutic–chemical
(ATC) code [20].
3. The Funen County Patient Administrative System
provides hospital discharge diagnosis for the
population of Funen County since 1977 for
inpatients and since 1989 for outpatients. The
diagnoses are encoded according to the International
Classification of Diseases eighth revision (ICD8) until
January 1994 and the International Classification of
Diseases 10th revision (ICD10) thereafter. The
International Classification of Diseases ninth revision
has never been used in Denmark.
4. The Danish Register of Causes of Death holds
information on all causes of death in Danish
citizens, encoded according to the ICD system. It is
mandatory by law to complete a death certificate in
any case of death in Denmark, and the National
Board of Health established the current register in
1875 [21].
Cohorts
Hyperuricemic individuals were included at the time of
their first synovial fluid examination for MSU crystals
during the period December 1999–March 2012. We
excluded individuals if at the time of inclusion they were
younger than 18 years of age or had a malignant
diagnosis in the 5 years preceding cohort entry (ICD10
C00–C96 excluding C44). We also excluded individuals
with other chronic inflammatory arthritic diseases (e.g.,
rheumatoid or psoriatic arthritis; ICD8 712; ICD10
M05–M07) prior to inclusion (Fig. 1).
Individuals entered the MSU crystal cohort if MSU
crystals were identified in at least one synovial fluid sam-
ple or tophus. Individuals without MSU crystals entered
the comparator “no-crystals” cohort. All individuals were
followed until the time of any of the following: main out-
come (see later), migration, death or end of study period.
Furthermore, to avoid immortal time bias, individuals
within the no-crystal cohort were censored if later syn-
ovial fluid examinations revealed MSU crystals, at which
time such individuals would contribute follow-up and
events to the MSU crystal exposed cohort. This was the
case for 11 (3.5 %) individuals in the no-crystal cohort.
Outcomes
The main outcome was the AntiPlatelet Trialists’
Collaboration (APTC) composite cardiovascular end-
point of nonfatal myocardial infarction (MI) (ICD10
I21–I22), nonfatal stroke (ICD10 I60–I64) and cardio-
vascular death (ICD10 I00–I99, R96–R99) [22].
Secondary outcomes were MI (ICD10 I21–I22), stroke
(ICD10 I60–I64), cardiovascular death (ICD10 I00–I99,
R96–R99) and all-cause mortality.
Data analysis
Our main analysis was carried out using propensity
score as a summary covariate to match patients with
and without MSU crystal precipitations. Using logistic
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regression, we calculated each individual’s propensity to
have joint precipitation of MSU crystals based on all rele-
vant cardiovascular risk covariates available at baseline.
Each individual with MSU crystals was then matched 1:1
to an individual without crystals, based on their propensity
scores. Pairwise nearest-neighbor matching was used, ap-
plying a caliper of 0.05 on a probability scale [23]. Vari-
ables included in the propensity score are presented in
Additional file 1. Because the plasma urate level may play
a key role in the pathogenesis of atherosclerotic cardiovas-
cular diseases, we chose to stratify by plasma urate levels,
but left this out of the propensity score model for
the main analysis. The urate strata were defined by
urate <0.30 mmol/l, 0.30–0.36 mmol/l, 0.36–0.42 mmol/l,
0.42–0.48 mmol/l, 0.48–0.54 mmol/l, 0.54–0.60 mmol/l,
0.60–0.68 mmol/l and ≥0.68 mmol/l. Hazard ratios (HRs)
with 95 % confidence intervals (CIs) were calculated using
the Cox proportional hazards model.
Use of a drug at baseline was defined by the redeem-
ing of a prescription for that particular drug inside
120 days prior to inclusion. Diagnoses were defined as
having the ICD8 or ICD10 code for hypertension (ICD8 40;
ICD10 I10), for example, at any time before inclusion.
The no-crystal group was set as reference for all
analyses.
All statistical analyses were carried out using STATA
version 13.1 (StataCorp, College Station, TX, USA).
Subgroup analyses
We performed preplanned subgroup analyses by age, sex,
renal function (using the National Kidney Foundation
chronic kidney disease stages [24]), diabetes and hyperten-
sion. In all subgroup analyses, the calculated propensity
score was added as an independent variable in the Cox
regression.
Sensitivity analysis
As shown previously, allopurinol can modify the cardio-
vascular risk [25–28], and hence previous use of allopur-
inol was included in the main analyses as part of the
propensity score model. To further investigate this issue
we ran the analysis excluding users of allopurinol prior
to cohort entry. To further investigate the effect of allo-
purinol we introduced allopurinol as a time-varying ex-
posure. We also ran the analysis including urate levels in
the propensity score model without stratification.
Some individuals might develop other inflammatory
arthritic diseases such as rheumatoid arthritis [29] or
psoriatic arthritis [30] during the follow-up period, both of
which are strongly associated with cardiovascular diseases.
Fig. 1 Study flow diagram. MSU monosodium urate
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Therefore, even though these were excluded at baseline,
we conducted an analysis censoring such individuals if
they acquired such a diagnosis during follow-up.
Ethics
The project was approved by the Danish Data Protection
Agency. Registry-based studies do not require patient
consent or ethical approval in Denmark [31]. After re-
trieval of source data, all data were anonymized and all
analyses were performed on a fully anonymized data set.
Results
In total, we identified 862 individuals with synovial fluid
examinations that met our selection criteria. After
matching, 634 individuals were included in the study:
317 individuals with MSU crystal precipitations and 317
individuals with no MSU crystals (Fig. 1). Except for
urate level, which was not included in the propensity
score, the baseline parameters were very well balanced.
The characteristics of MSU exposed and unexposed in-
dividuals are presented in Table 1.
For MSU exposed and unexposed, the event rates were
45 per 1000 person-years and 34 per 1000 person-years
respectively. Cox proportional hazard regression for MSU
exposed individuals demonstrated an HR stratified for
urate levels for APTC events of 0.86 (95 % CI 0.52–1.44)
compared with the unexposed group (Table 2).
For the outcomes of strokes and MIs alone, no associ-
ations with the presence of MSU crystals were found
(Table 2).
For cardiovascular mortality and all-cause mortality
among MSU crystal exposed individuals compared
with nonexposed individuals the HR was 0.58 (95 %
CI 0.26–1.31) and 0.74 (95 % CI 0.45–1.21) respect-
ively (Table 2).
We failed to identify any subgroups associated with al-
tered cardiovascular risk attributable to the presence or
absence of MSU crystal precipitation (Table 3).
When changing the exclusion criteria to comprise pre-
vious allopurinol users, the presence of MSU crystals
had a significant protective effect on cardiovascular
death, while other outcomes remained nonsignificant.
Table 1 Baseline characteristics of MSU crystal exposed and
propensity score matched unexposed individuals
MSU crystals No crystals
All 317 (100.0) 317 (100.0)
Male 277 (87.4) 275 (86.8)
Female 40 (12.6) 42 (13.2)
Age 61 (50–74) 62 (50–74)
History of
Ischemic heart disease 77 (24.3) 74 (23.3)
Heart failure 48 (15.1) 45 (14.2)
Atrial fibrillation 54 (17.0) 54 (17.0)
Stroke 38 (12.0) 34 (10.7)
Diabetes mellitus 48 (15.1) 40 (12.6)
Hypertension 109 (34.4) 100 (31.5)
COPD 33 (10.4) 30 (9.5)
Charlson comorbidity index
0 147 (46.4) 152 (47.9)
1 62 (19.6) 62 (19.6)
2 39 (12.3) 41 (12.9)
≥3 69 (21.8) 62 (19.6)
Current drug use (baseline)
Urate-lowering drugs 49 (15.5) 46 (14.5)
Diabetes drugs (ever use) 41 (12.9) 33 (10.4)
Vitamin K antagonists 36 (11.4) 34 (10.7)
ADP-receptor inhibitor 8 (2.5) 6 (1.9)
Low-dose ASA 64 (20.2) 56 (17.7)
Dipyridamole 11 (3.5) 11 (3.5)
Digitalis 28 (8.8) 29 (9.1)
Nitrates 15 (4.7) 15 (4.7)
Thiazide diuretics 27 (8.5) 28 (8.8)
Loop diuretics 86 (27.1) 85 (26.8)
Aldosterone antagonists 15 (4.7) 14 (4.4)
Beta blockers 61 (19.2) 60 (18.9)
Calcium antagonists 45 (14.2) 46 (14.5)
RAS blockers 104 (32.8) 101 (31.9)
Statins 64 (20.2) 56 (17.7)
COPD drugs 33 (10.4) 32 (10.1)
Systemic corticosteroids 56 (17.7) 56 (17.7)
NSAIDs 166 (52.4) 161 (50.8)
Blood measurements (baseline)
Urate level 0.53 (0.46–0.61) 0.43 (0.38–0.50)
Urate level <0.30 mmol/l 0 (0.0) 0 (0.0)
Urate level 0.30–0.36 mmol/l 7 (2.2) 28 (8.8)
Urate level 0.37–0.42 mmol/l 43 (13.6) 129 (40.7)
Urate level 0.43–0.48 mmol/l 72 (22.7) 65 (20.5)
Urate level >0.48 mmol/l 195 (61.5) 95 (30.0)
Table 1 Baseline characteristics of MSU crystal exposed and
propensity score matched unexposed individuals (Continued)
eGFR 68 (51–83) 70 (53–81)
High HbA1c (>6.5 %) 36 (11.4) 26 (8.2)
High total cholesterol (>5 mmol/l) 64 (20.2) 67 (21.1)
Proteinuria 43 (13.6) 38 (12.0)
Data presented as n (%) or median (IQR)
ADP adenosine diphosphate, ASA acetyl salicylic acid, COPD chronic
obstructive pulmonary disease, eGFR estimated glomerular filtration rate,
HbA1c hemoglobin A1c, IQR interquartile range, MSU monosodium urate,
NSAID nonsteroidal anti-inflammatory drug, RAS renin–angiotensin system
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The analysis introducing time-varying allopurinol ex-
posure and other sensitivity analyses did not change the
results (see Additional file 2).
Discussion
We have shown that, among hyperuricemic individuals,
MSU crystal precipitation does not influence the risk of
cardiovascular events when other important prognostic
factors such as urate levels are adjusted for.
In contrast to our findings, most studies have reported
increased cardiovascular risk among gout patients [4, 5, 32].
These studies, however, do not rely on gout being
diagnosed according to international guidelines, but are
instead based on either self-reported gout or serial
measurement of elevated urate or a combination of dif-
ferent measures [4, 5, 32].
Strengths
Our study included all individuals with joint fluid sample
for MSU crystals during a 12-year period in Funen
County, Denmark. This region has a stable population
and we were able to account for migration during the
study period on the individual level. In contrast to most
other studies, our study is based solely on individuals
with joint fluid or tophi examinations for MSU crystals
[4, 5, 32], which is in line with international recommen-
dations for gout diagnosis [7, 33]. We had access to all
blood samples including MSU crystal determinations of
every patient. In addition, we had full coverage of
admissions, outpatient visits, prescription data and
causes of death.
Limitations
Data on some potential confounders were not available,
most importantly smoking status, which is a well-known
risk factor for ischemic heart disease [34]. However, to
our knowledge, there is no association between smoking
and MSU precipitation for a given elevated urate level.
Consequently, smoking is unlikely to be an important
confounder in our study.
The final number of eligible individuals was small
compared with the large source population the sample
was derived from. This was primarily due to the small
number of joint fluid and tophi samples made for MSU
crystal determinations. The small number of MSU
crystal determinations is surprising, given that a definite
diagnose of gout is based on the presence of MSU
crystal deposition [7] and more than 4000 individuals
from the Funen population redeemed at least one pre-
scription for the urate-lowering drug allopurinol during
2010 [35].
We did not have access to the indication for the joint
fluid examinations. Individuals who undergo this pro-
cedure are likely to have a swollen joint and hence some
type of arthritis. If the primary causal pathway between
gout and cardiovascular disease is mediated through
Table 2 Cardiovascular events among propensity score-matched MSU crystal exposed and unexposed individuals
MSU crystals No MSU crystals HR (95 % CI) HR (95 % CI)
(events / person-year) (events / person-year) no stratification by urate level stratified by urate level
APTC 46 / 1026 34 / 1009 1.33 (0.85–2.07) 0.86 (0.52–1.43)
Nonfatal MI 11 / 1026 9 / 1009 1.22 (0.50–2.94) 1.04 (0.37–2.90)
Nonfatal stroke 17 / 1026 11 / 1009 1.50 (0.70–3.20) 1.13 (0.49–2.61)
CV death 18 / 1026 14 / 1009 1.27 (0.63–2.56) 0.59 (0.26–1.32)
All-cause mortality 46 / 1026 40 / 1009 1.14 (0.75–1.74) 0.74 (0.45–1.21)
APTC AntiPlatelet Trialists’ Collaboration, CI confidence interval, CV cardiovascular, HR Hazard ratio, MI myocardial infarction, MSU monosodium urate
The no-crystal group was set as reference
Table 3 Cardiovascular events of MSU crystal exposed and
unexposed by subgroups
MSU crystals No crystals Hazard ratio
(95 % CI)
(events /
person-years)
(events /
person-years)
PS adjusted*
All 46 / 1026 34 / 1009 0.86 (0.52–1.43)
Age <60 14 / 698 4 / 577 1.31 (0.42–4.15)
Age 60–79 15 / 240 20 / 370 0.79 (0.36–1.76)
Age 80+ 17 / 88 10 / 62 0.79 (0.31–1.97)
Male 40 / 951 31 / 896 0.82 (0.47–1.41)
Female 6 / 75 3 / 113 1.87 (0.33–10.57)
No previous APTC 30 / 950 24 / 958 0.92 (0.48–1.74)
Only previous APTC 16 / 76 10 / 51 0.73 (0.28–1.94)
CKD 4 + 5 8 / 41 3 / 74 2.57 (0.57–11.55)
CKD 3 18 / 190 11 / 164 1.24 (0.54–2.86)
CKD 2 8 / 580 19 / 611 0.35 (0.13–0.89)
CKD 1 10 / 163 1 / 131 3.72 (0.44–31.23)
DM 11 / 103 9 / 102 0.79 (0.28–2.23)
No DM 35 / 923 25 / 907 0.93 (0.51–1.69)
Hypertension 22 / 245 10 / 214 1.69 (0.76–3.78)
Normotensive 24 / 781 24 / 795 0.64 (0.32–1.26)
APTC AntiPlatelet Trialists’ Collaboration, CI confidence interval, CKD chronic
kidney disease stages, DM diabetes mellitus, MSU monosodium urate,
PS propensity score
*All subgroups are PS adjusted. The no-crystal group was set as reference
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joint inflammation, we might have underestimated the
true effect of MSU precipitation, since our reference co-
hort to some extent had also been affected by inflamma-
tion. We attempted to address this by excluding subjects
with other established chronic arthritis, but we cannot
rule out that there is some residual bias towards the null.
Finally, with a known link between gout and cardio-
vascular disease, there might be more focus on cardio-
vascular health in the gout patients. We believe,
however, that our very hard endpoints would come to
medical attention under all circumstances, whether the
patients had gout or not.
Our results can be interpreted in one of four ways. First,
the presence of MSU crystals might not influence the car-
diovascular disease risk, and the increased risk of cardio-
vascular disease among gout patients is mediated through
other modes of action than the low-grade inflammation
induced by crystal deposition [36]. Second, there might be
a contribution of urate precipitation to the cardiovascular
risk of a gout patient [37], but it is too small to be mea-
sured in our setup, given that hyperuricemic patients
already have a clearly elevated risk and given the some-
what limited power in our study. Third, synovial fluid ex-
aminations do not have perfect sensitivity [38, 39]. We
can therefore not rule out that some individuals in the no-
crystal group did in fact have MSU crystal precipitations.
However, only 2 % (28 out of 1566) of negative first fluid
examinations in our material showed positive urate pre-
cipitation at a later examination. Finally, even though we
excluded patients with other inflammatory arthritis, the
no-crystal group could possibly be even more burdened
with systemic inflammation [40] than the MSU crystal
group, since the indication for joint fluid examinations for
crystals not only includes crystal precipitation diseases but
also co-examinations of patients suspected to suffer from
other arthritis or from infectious joint disease.
Conclusion
The presence or absence of MSU crystal precipitations in
hyperuricemic individuals does not seem to be important
for individuals’ cardiovascular risk. Future studies hope-
fully will reveal the pathophysiological mechanism behind
the increased risk of cardiovascular diseases among gout
patients.
Additional files
Additional file 1: Is a table presenting additional information on
the variables included in the propensity score model. (DOCX 20 kb)
Additional file 2: Presents the results from the sensitivity analyses.
(DOCX 113 kb)
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